Table 1.
Demographic data of the 38 study subjects
| Variable | Treatment groups
|
All subjects (N=38) | P-valuea | |||
|---|---|---|---|---|---|---|
| 150 mg (n=10) | 300 mg (n=10) | 450 mg (n=9) | 600 mg (n=9) | |||
|
|
|
|
|
|
|
|
| Age (years) | 24.9±2.5 | 23.8±1.6 | 25.3±1.5 | 24.8±3.5 | 24.7±2.4 | 0.5570 |
| Weight (kg) | 74.44±8.67 | 68.58±6.85 | 70.76±4.81 | 71.11±11.87 | 71.24±8.36 | 0.4893 |
| Height (cm) | 175.89±5.18 | 173.06±5.96 | 173.14±3.86 | 172.08±7.26 | 173.59±5.65 | 0.5008 |
| BMI (kg/m2) | 24.14±3.48 | 22.88±1.70 | 23.60±1.61 | 23.87±2.15 | 23.62±2.33 | 0.6751 |
Notes: Treatment 1 (150 mg): GLA5PR GLARS-NF1 150 mg tablet; treatment 2 (300 mg): GLA5PR GLARS-NF1 300 mg tablet; treatment 3 (450 mg): GLA5PR GLARS-NF1 150 mg+300 mg tablets; treatment 4 (600 mg): GLA5PR GLARS-NF1 two 300 mg tablets; all treatments were after standard meal.
a
ANOVA was used. Data are presented as mean ± standard deviation.
Abbreviation: BMI, body mass index.